We solved the crystal structure of c-Src KD in complex with Ponatinib (Fig. 6a, b), a type-II tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL)50,51. This evidence concerns the gene SRC and acute lymphoblastic leukemia.